Gonadorelin vs Sermorelin
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Gonadorelin
Gonadorelin is a synthetic form of gonadotropin-releasing hormone (GnRH). It stimulates the pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), supporting natural hormone production.
Full details →Sermorelin
Sermorelin is a synthetic analog of GHRH consisting of the first 29 amino acids of the natural hormone. It was previously FDA-approved for GH deficiency diagnosis and treatment in children.
Full details →Side-by-Side Comparison
| Aspect | Gonadorelin | Sermorelin |
|---|---|---|
| Dose Range | 100 mcg–200 mcg | 100 mcg–300 mcg |
| Frequency | 2x daily | 1x daily |
| Cycle Length | 8–12 weeks | 8–12 weeks |
| Route | subcutaneous | subcutaneous |
| Mechanism | Binds to GnRH receptors in the pituitary gland, triggering pulsatile release of LH and FSH. This stimulates testicular or ovarian function and natural sex hormone production. | Binds to GHRH receptors in the pituitary gland to stimulate natural GH production and release. Maintains the body's natural feedback mechanisms for GH regulation. |
| Typical Dosage | Men: 100-200mcg subcutaneously 2-3 times daily. Women (fertility): Per clinical protocol. HRT support: Often combined with other therapies. | Typical dosing: 200-500mcg administered once daily, usually before bed. Some protocols use twice daily dosing. |
| Administration | Subcutaneous injection. Pulsatile administration mimics natural GnRH release patterns. Often used during or after testosterone therapy. | Subcutaneous injection, preferably at bedtime to work with natural GH release patterns. Can be combined with GHRPs for synergistic effects. |
| Side Effects | Headache, flushing, injection site reactions. In women may cause ovarian hyperstimulation. Generally well-tolerated. | Generally well-tolerated. May cause injection site reactions, headache, flushing, or dizziness. Less side effects than direct GH administration. |
| Best For |
Key Differences
Unique to Gonadorelin:
Unique to Sermorelin:
Key Studies
Gonadorelin
- Effect of gonadorelin dose and an additional gonadorelin treatment 2 days after the initiation of Resynch-25 on ovarian dynamics and fertility of lactating Holstein cows.
Journal of dairy science, 2025
- Effect of 200 μg of gonadorelin hydrochloride at the first GnRH of a CO-Synch program on ovulation rate and pregnancies per artificial insemination in Holstein heifers.
Journal of dairy science, 2024
- Effect of 200 µg of gonadorelin at the first gonadotropin-releasing hormone of the Resynch-25 on ovarian dynamics and fertility in lactating Holstein cows.
Journal of dairy science, 2024
Sermorelin
- A potentially effective drug for patients with recurrent glioma: sermorelin.
Annals of translational medicine, 2021
- Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?
Clinical interventions in aging, 2006
- Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 1999
Ready to Learn More?
Looking for trusted sources?